Scientists Develop Genome Editing Technique for Self-Sustaining Weight Loss in Mice

Researchers from the University of Osaka have pioneered a groundbreaking approach that enables mice to produce their own weight-loss medication through genome editing. This innovative method offers a potential long-term solution to obesity treatment, eliminating the need for frequent injections.

The study, published in Communications Medicine, describes how a newly introduced gene in mice triggers the liver to continuously produce Exenatide, a glucagon-like peptide-1 receptor agonist commonly used to promote weight loss and improve glucose metabolism. By integrating this gene into the mouse genome, scientists created a biological reservoir that maintained steady levels of the medication in the bloodstream over several months.

This approach stands out by combining genome editing with biologic therapy, targeting complex diseases like obesity that are not caused by a single genetic mutation. Unlike traditional gene therapy, which generally corrects genetic defects, this method introduces a new protein-coding gene to produce therapeutic benefits long-term.

In the study, the genome-edited mice displayed reduced food intake, lower body weight, and improved glucose regulation without observable side effects. The increased and sustained production of Exenatide from liver cells led to better insulin sensitivity and glucose metabolism, demonstrating the potential for in-body drug production to transform treatment strategies.

Senior author Keiichiro Suzuki highlighted that this technique could be applicable to various diseases lacking a direct genetic cause, potentially streamlining treatments by reducing the need for repeated drug administration. This innovative strategy could revolutionize how chronic conditions like diabetes and obesity are managed, offering more effective and patient-friendly options.

Source: https://medicalxpress.com/news/2025-07-genome-enables-mice-weight-loss.html